576 related articles for article (PubMed ID: 8939269)
41. Efficacy of grass pollen sublingual immunotherapy for three consecutive seasons and after cessation of treatment: the ECRIT study.
Ott H; Sieber J; Brehler R; Fölster-Holst R; Kapp A; Klimek L; Pfaar O; Merk H
Allergy; 2009 Jan; 64(1):179-86. PubMed ID: 19076534
[TBL] [Abstract][Full Text] [Related]
42. Sublingual-swallow immunotherapy with standardized 3-grass pollen extract: a double-blind, placebo-controlled study.
de Blay F; Barnig C; Kanny G; Purohit A; Leynadier F; Tunon de Lara JM; Chabane H; Guérin L;
Ann Allergy Asthma Immunol; 2007 Nov; 99(5):453-61. PubMed ID: 18051216
[TBL] [Abstract][Full Text] [Related]
43. Preventive symptomatic immunotherapy versus placebo in seasonal rhinitis due to grasses in children and to Parietaria in adult patients.
Troise C; Bignardi D; Modena P; Pissacroia C; Di Berardino F
Allerg Immunol (Paris); 2000 Jun; 32(6):246-9. PubMed ID: 10971859
[TBL] [Abstract][Full Text] [Related]
44. Agreement of efficacy assessments for five-grass pollen sublingual tablet immunotherapy.
Didier A; Melac M; Montagut A; Lhéritier-Barrand M; Tabar A; Worm M
Allergy; 2009 Jan; 64(1):166-71. PubMed ID: 19076546
[TBL] [Abstract][Full Text] [Related]
45. A randomized controlled trial of sublingual immunotherapy for Japanese cedar pollinosis.
Horiguchi S; Okamoto Y; Yonekura S; Okawa T; Yamamoto H; Kunii N; Sakurai D; Fujimura T; Nakazawa K; Yasueda H
Int Arch Allergy Immunol; 2008; 146(1):76-84. PubMed ID: 18087165
[TBL] [Abstract][Full Text] [Related]
46. Dose dependence of immunological response to sublingual immunotherapy.
Marcucci F; Sensi L; Di Cara G; Incorvaia C; Frati F
Allergy; 2005 Jul; 60(7):952-6. PubMed ID: 15932387
[TBL] [Abstract][Full Text] [Related]
47. Effects of sublingual immunotherapy in patients sensitised to Ambrosia. An open controlled study.
Valle C; Bazzi S; Berra D; Sillano V; Puccinelli P; Parmiani S
Allergol Immunopathol (Madr); 2000; 28(6):311-7. PubMed ID: 11269898
[TBL] [Abstract][Full Text] [Related]
48. Clinical efficacy and tolerance of two year Lolium perenne sublingual immunotherapy.
Gozalo F; Martín S; Rico P; Alvarez E; Cortés C
Allergol Immunopathol (Madr); 1997; 25(5):219-27. PubMed ID: 9395005
[TBL] [Abstract][Full Text] [Related]
49. Canadian trial of sublingual swallow immunotherapy for ragweed rhinoconjunctivitis.
Bowen T; Greenbaum J; Charbonneau Y; Hebert J; Filderman R; Sussman G; Del Carpio J; Gold M; Keith P; Moote W; Cecchetto S; Cecchetto O; Sharp D; Broutin O; André C
Ann Allergy Asthma Immunol; 2004 Nov; 93(5):425-30. PubMed ID: 15562880
[TBL] [Abstract][Full Text] [Related]
50. Sublingual-oral administration of standardized allergenic extracts: phase 1 safety and dosing results.
Esch RE; Bush RK; Peden D; Lockey RF
Ann Allergy Asthma Immunol; 2008 May; 100(5):475-81. PubMed ID: 18517081
[TBL] [Abstract][Full Text] [Related]
51. Sublingual immunotherapy with grass pollen is not effective in symptomatic youngsters in primary care.
Röder E; Berger MY; Hop WC; Bernsen RM; de Groot H; Gerth van Wijk R
J Allergy Clin Immunol; 2007 Apr; 119(4):892-8. PubMed ID: 17321581
[TBL] [Abstract][Full Text] [Related]
52. [Sublingual immunotherapy in children with grass pollen induced allergic rhinoconjunctivitis].
Wolthers OD; Høst A; Frederiksen B; Halken S
Ugeskr Laeger; 2012 Aug; 174(35):1989-92. PubMed ID: 22929576
[TBL] [Abstract][Full Text] [Related]
53. Randomized controlled trial of high-dose sublingual immunotherapy to treat seasonal allergic rhinitis.
Smith H; White P; Annila I; Poole J; Andre C; Frew A
J Allergy Clin Immunol; 2004 Oct; 114(4):831-7. PubMed ID: 15480323
[TBL] [Abstract][Full Text] [Related]
54. Specific immunotherapy with SQ standardized grass allergen tablets in asthmatics with rhinoconjunctivitis.
Dahl R; Stender A; Rak S
Allergy; 2006 Feb; 61(2):185-90. PubMed ID: 16409194
[TBL] [Abstract][Full Text] [Related]
55. Efficacy and safety of subcutaneous immunotherapy with a biologically standardized extract of Ambrosia artemisiifolia pollen: a double-blind, placebo-controlled study.
Mirone C; Albert F; Tosi A; Mocchetti F; Mosca S; Giorgino M; Pecora S; Parmiani S; Ortolani C
Clin Exp Allergy; 2004 Sep; 34(9):1408-14. PubMed ID: 15347374
[TBL] [Abstract][Full Text] [Related]
56. Economic evaluation of sublingual vs subcutaneous allergen immunotherapy.
Pokladnikova J; Krcmova I; Vlcek J
Ann Allergy Asthma Immunol; 2008 May; 100(5):482-9. PubMed ID: 18517082
[TBL] [Abstract][Full Text] [Related]
57. Impact of sublingual immunotherapy on seasonal asthma and skin reactivity in children allergic to Parietaria pollen treated with inhaled fluticasone propionate.
Pajno GB; Vita D; Parmiani S; Caminiti L; La Grutta S; Barberio G
Clin Exp Allergy; 2003 Dec; 33(12):1641-7. PubMed ID: 14656349
[TBL] [Abstract][Full Text] [Related]
58. Analysis of allergen immunotherapy studies shows increased clinical efficacy in highly symptomatic patients.
Howarth P; Malling HJ; Molimard M; Devillier P
Allergy; 2012 Mar; 67(3):321-7. PubMed ID: 22142377
[TBL] [Abstract][Full Text] [Related]
59. Effect of grass pollen immunotherapy with Alutard SQ on quality of life in seasonal allergic rhinoconjunctivitis.
Powell RJ; Frew AJ; Corrigan CJ; Durham SR
Allergy; 2007 Nov; 62(11):1335-8. PubMed ID: 17714551
[TBL] [Abstract][Full Text] [Related]
60. Clinical and immunologic effects of a rush sublingual immunotherapy to Parietaria species: A double-blind, placebo-controlled trial.
Passalacqua G; Albano M; Riccio A; Fregonese L; Puccinelli P; Parmiani S; Canonica GW
J Allergy Clin Immunol; 1999 Nov; 104(5):964-8. PubMed ID: 10550740
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
